Anzeige
Erschienen in:
24.10.2016 | Computer Applications
Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings
Erschienen in: European Radiology | Ausgabe 10/2017
Einloggen, um Zugang zu erhaltenAbstract
Objective
Despite 90 % of glioblastoma (GBM) recurrences occurring in the peritumoral brain zone (PBZ), its contribution in patient survival is poorly understood. The current study leverages computerized texture (i.e. radiomic) analysis to evaluate the efficacy of PBZ features from pre-operative MRI in predicting long- (>18 months) versus short-term (<7 months) survival in GBM.
Methods
Sixty-five patient examinations (29 short-term, 36 long-term) with gadolinium-contrast T1w, FLAIR and T2w sequences from the Cancer Imaging Archive were employed. An expert manually segmented each study as: enhancing lesion, PBZ and tumour necrosis. 402 radiomic features (capturing co-occurrence, grey-level dependence and directional gradients) were obtained for each region. Evaluation was performed using threefold cross-validation, such that a subset of studies was used to select the most predictive features, and the remaining subset was used to evaluate their efficacy in predicting survival.
Results
A subset of ten radiomic ‘peritumoral’ MRI features, suggestive of intensity heterogeneity and textural patterns, was found to be predictive of survival (p = 1.47 × 10-5) as compared to features from enhancing tumour, necrotic regions and known clinical factors.
Conclusion
Our preliminary analysis suggests that radiomic features from the PBZ on routine pre-operative MRI may be predictive of long- versus short-term survival in GBM.
Key Points
• Radiomic features from peritumoral regions can capture glioblastoma heterogeneity to predict outcome.
• Peritumoral radiomics along with clinical factors are highly predictive of glioblastoma outcome.
• Identifying prognostic markers can assist in making personalized therapy decisions in glioblastoma.